AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21346616
Drug: Quetiapine 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 1200 mg/d
Trial: 21733490
Drug: Quetiapine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 800 mg/d
Trial: 9350607
Drug: Vancomycin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (5 mg/kg/day bid)
Trial: 9350607
Drug: Teicoplanin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (5 mg/kg/day once daily)
Trial: 29125700
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C (2 × 25 mg)
Trial: 29125700
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D (2 × 12.5 mg)
Trial: 29125700
Drug: Formulation E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulation E (2 × 12.5 mg)
Trial: 29125700
Drug: Formulation C
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C (1 × 25 mg) under fed conditions
Trial: 22305026
Drug: 4 oz
RxNorm normalized name: Oval Amber 4 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 oz of cranberry juice daily
Trial: 22305026
Drug: 8 oz
RxNorm normalized name: Ointment Jar 8 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 oz of cranberry juice daily
Trial: 14578019
Drug: Apomorphine (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (0.005 mg/kg)
Trial: 31725748
Drug: Nitrogen balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen balance measurement (g/24h)
Trial: 30576544
Drug: Netupitant 300
RxNorm normalized name: netupitant 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netupitant 300 mg
Trial: 24122871
Drug: Netupitant 450
RxNorm normalized name: Netupitant
DrugBank: Netupitant (DB09048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netupitant 450 mg
Trial: 24122871
Drug: [(14) C]‐netupitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(14) C]‐netupitant 300 mg (ADME study)
Trial: 9471921
Drug: Chronic exposure
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic exposure to carbon disulphide (CS2) at concentrations of 9.36‐23.4 mg/m3
Trial: 3315594
Drug: Intravenous anisoylated
RxNorm normalized name: Anisoylated plasminogen streptokinase activator complex
DrugBank: Anistreplase (DB00029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC) 30U
Trial: 3315594
Drug: Heparin 5000U
RxNorm normalized name: HEPARIN NA BEEF 5000U/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5000U
Trial: 21091220
Drug: Irbesartan/HCTZ 150/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ 150/12.5 mg
Trial: 21091220
Drug: Valsartan/HCTZ 80/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ 80/12.5 mg
Trial: 18220941
Drug: Aggrenox (antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggrenox (antiplatelet agent)
Trial: 18220941
Drug: NXY (free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY (free radical trapping agent)
Trial: 18220941
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (for prevention of deep vein thrombosis post-stroke)
Trial: 15121566
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg daily, oral)
Trial: 15121566
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (intravenous)
Trial: 9876475
Drug: High-dose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroid (prednisone or dexamethasone) during remission induction
Trial: 9876475
Drug: Chemotherapy-maintained remission
RxNorm normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy-maintained remission
Trial: 31822885
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (favipiravir and oseltamivir)
Trial: 24632748
Drug: Oseltamivir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir monotherapy
Trial: 25400284
Drug: Viagra (original)
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Viagra (original) 100 mg
Trial: 25400284
Drug: Edyfil (generic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edyfil (generic) 100 mg
Trial: 19395984
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/d for 1 month, followed by a taper of 30 mg/d for 22 weeks)
Trial: 16547904
Drug: Group reminiscence
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group reminiscence therapy (9 weekly one-hour sessions)
Trial: 23109680
Drug: Nutrient-enriched formula
RxNorm normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrient-enriched formula (treatment B)
Trial: 23109680
Drug: Term formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Term formula (treatment A)
Trial: 15608435
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 2.0 mg/day, pyridoxine 25 mg/day, and cobalamin 0.5 mg/day (active VITATOPS medication)
Trial: 18566295
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg/d)
Trial: 2669998
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (S)
Trial: 2669998
Drug: Standard plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard plus intermediate-dose methotrexate (SAM)
Trial: 22921481
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment (10mg/day initially, increased to 10-20mg/day)
Trial: 12454840
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/day
Trial: 19457141
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/day (nonresponders who entered rollover study ETV-901)
Trial: 14627785
Drug: Efalizumab 1
RxNorm normalized name: efalizumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 1 mg/kg/week
Trial: 14627785
Drug: Efalizumab 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 2 mg/kg/week
Trial: 14627785
Drug: Efalizumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (after discontinuation at week 24)
Trial: 16786816
Drug: Brief Strategic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Strategic Family Therapy (BSFT) for 12 weeks
Trial: 10371474
Drug: Cefazolin, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin, 1 g/1,000 mL, amnioinfusion
Trial: 8688279
Drug: Colloid (polygeline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid (polygeline, Haemaccel) 8 ml kg‐1 (n = 15)
Trial: 29038320
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (2 doses at 12-24 months)
Trial: 18591547
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg daily)
Trial: 26802155
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg b.i.d.)
Trial: 26802155
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of selumetinib (150 mg daily) with erlotinib (100 mg daily)
Trial: 24581940
Drug: Control-dose conformal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control-dose conformal radiotherapy (64 Gy in 32 fractions)
Trial: 24581940
Drug: Escalated-dose conformal
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated-dose conformal radiotherapy (74 Gy in 37 fractions)
Trial: 21877138
Drug: Chained sequential
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chained sequential operations
Trial: 17296878
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy with good INR control (>75%)
Trial: 27137148
Drug: Quetiapine 25
RxNorm normalized name: quetiapine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 25 mg immediate-release tablets
Trial: 20593742
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch
Trial: 20502014
Drug: Rivastigmine capsules
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine capsules
Trial: 19272499
Drug: Four different
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four different gel formulations
Trial: 7935815
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride (beta-adrenergic receptor antagonist)
Trial: 2232919
Drug: Monitoring and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring and feedback using an electronic device that records the time and day pills are removed
Trial: 21767103
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy (immediate therapy)
Trial: 21767103
Drug: Delayed antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antiretroviral therapy (after decline in CD4 count or onset of symptoms)
Trial: 17116721
Drug: Heat-killed Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Lactobacillus plantarum L-137 (HK-LP) 10 mg daily for 12 weeks
Trial: 14746696
Drug: Eradicating treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradicating treatment with omeprazole, amoxicillin, and clarithromycin for 7 days (group A, n = 47)
Trial: 14746696
Drug: Placebo, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, amoxicillin, and clarithromycin for 7 days (group B, n = 46)
Trial: 11203593
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid treatment
Trial: 11210244
Drug: Tetracycline hydrochloride
RxNorm normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline hydrochloride treatment
Trial: 11210244
Drug: EDTA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA treatment
Trial: 26272524
Drug: CF threshold
RxNorm normalized name: californium Cf-249
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF threshold of >8 g
Trial: 22689416
Drug: Intensive cholesterol-lowering
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cholesterol-lowering therapy with pitavastatin (target LDL-C; 80 mg/dl)
Trial: 22689416
Drug: Moderate cholesterol-lowering
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate cholesterol-lowering therapy with pitavastatin (target LDL-C; 100 mg/dl)
Trial: 21612319
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelaic acid 5% and clindamycin 2% (AA-Clin)
Trial: 12888870
Drug: Antithrombin infusions
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin infusions
Trial: 12888870
Drug: No antithrombin
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombin treatment (control)
Trial: 10877248
Drug: UVB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB treatment with optimized doses based on skin pigmentation measurements
Trial: 10877248
Drug: Conventional UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional UVB treatment regimen with fixed dose increments
Trial: 27541029
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics
Trial: 23807984
Drug: Gynofit (vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynofit (vaginal and perineal dose)
Trial: 21144773
Drug: Pentoxifylline (PTF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTF) 1200 mg/day for 24 months
Trial: 9053501
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 followed by cisplatin 100 mg/m2
Trial: 9053501
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 followed by cisplatin 75 mg/m2
Trial: 9053501
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Trial: 8977598
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 micrograms twice daily
Trial: 7952551
Drug: Terbutaline 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1,000 micrograms three times daily
Trial: 29533368
Drug: YYSG (Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYSG (Chinese herbal medicine capsules)
Trial: 22771050
Drug: AXOS 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXOS 4.8 g/d
Trial: 22771050
Drug: AXOS 2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXOS 2.2 g/d
Trial: 22771050
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g/d AXOS)
Trial: 16243127
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate 20 mg plus metronidazole 0.75% topical lotion
Trial: 16243127
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus metronidazole 0.75% topical lotion
Trial: 8119599
Drug: Hemorheological manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemorheological manipulation including plasma expansion with hydroxyethyl-starch, withdrawal of whole blood if hematocrit was above 42%, and parenteral pentoxifylline.
Trial: 2605993
Drug: Active marijuana
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active marijuana (0-2.7% delta 9 THC), 4 cigarettes smoked daily, 2 prior to and 2 during social access period.
Trial: 786676
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of AN 448 t.i.d.
Trial: 24884731
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol at 0.7 g/kg
Trial: 24884731
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol at 1.0 g/kg
Trial: 24884731
Drug: 20% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% mannitol at 1.4 g/kg
Trial: 11488118
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate solution
Trial: 9460311
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with intravenous oxytocin
Trial: 9460311
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with vaginal prostaglandin E2 gel
Trial: 30727931
Drug: Direct Antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Antiviral Agents (DAAs), sofosbuvir-based therapies for 12 weeks
Trial: 28930864
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg·d)
Trial: 11159230
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg every 6 h
Trial: 11159230
Drug: Metamizol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol 1 g every 6 h
Trial: 22584689
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g every 6 h
Trial: 2906888
Drug: SASP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SASP (1 g, n = 21)
Trial: 2906888
Drug: SAB (0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAB (0.72 g, n = 22)
Trial: 2044398
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg naftidrofuryl twice daily in slow-release form
Trial: 31165457
Drug: Sugammadex (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (4 mg·kg−1)
Trial: 31165457
Drug: Neostigmine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (40 µg)
Trial: 27771984
Drug: Desflurane inhalation
RxNorm normalized name: Desflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desflurane inhalation anesthesia (Group I)
Trial: 27771984
Drug: Propofol total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol total intravenous anesthesia with ischemic preconditioning (Group TIP)
Trial: 26009577
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) plus standard therapy of intravenous methylprednisolone (IVMP)
Trial: 26009577
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy of intravenous methylprednisolone (IVMP)
Trial: 16620355
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin lispro (0.075 U/kg/hour after a bolus of 0.15 U/kg IV regular insulin)
Trial: 16620355
Drug: Intravenous regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regular insulin (bolus of 0.15 U/kg followed by infusion)
Trial: 9226738
Drug: 20 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms/kg nicotine by nasal spray
Trial: 9226738
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of nicotine
Trial: 9226738
Drug: Generalization doses
RxNorm normalized name: albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generalization doses
Trial: 9226738
Drug: Confidence in
RxNorm normalized name: miconazole nitrate Topical Cream [Clearly Confident]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidence in discriminating training doses
Trial: 7944440
Drug: Continuous arterial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous arterial infusion group
Trial: 7944440
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose arterial infusion group
Trial: 7944440
Drug: Repeated one-shot
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated one-shot arterial infusion group
Trial: 7944440
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose arterial infusion of 5-FU
Trial: 9598255
Drug: Thiopentone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (5 mg.kg‐1)
Trial: 9598255
Drug: Thiopentone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone plus Atracurium (5 mg.kg‐1 thiopentone plus 0.05 mg.kg‐1 atracurium)
Trial: 7945786
Drug: Balsam of
RxNorm normalized name: Balsam of Peru
DrugBank: Balsam of Peru (DB11482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsam of Peru (225 mg)
Trial: 28235882
Drug: Pembrolizumab (KEYTRUDA)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (KEYTRUDA) at a dose of 2 mg/kg every 3 weeks by intravenous infusion
Trial: 25352527
Drug: treatment-as-usual condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual condition
Trial: 19687393
Drug: High-frequency treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency treatment
Trial: 19687393
Drug: Electrocautery treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrocautery treatment